Zum Inhalt springen
Sponsorship
Die MVF-Knowledge-HubsFrisch aus der Forschung. Täglich aktualisiert!

Suchen Sie in Hunderten nationaler und internationaler Datenbanken nach dem neuesten Studienwissen der angegebenen Themengebiete und/oder lassen Sie sich werktäglich per Newsletter informieren. Die Newsfeeds werden auf deutsch übersetzt and nach Übertragbarkeit auf das deutsche Gesundheits-/Versorgungssystem ausgewählt:

Zu den Knowledge-Hubs

Gliptins with increasing supply relevance

The drug therapy for type 2 diabetes mellitus is being put to the test again with the stock market call on April 1, 2013. As early as 2011, every second euro of oral antidiabetic drugs (OADs) was spent on DPP-IV inhibitors (cf. Bensing/Kleinfeld 2012), and this share has now increased to almost 63 percent. The significant increases in expenditure (according to list prices) for OAD tend to be offset by constant prescription quantities.

Read more
First publication date: 28.05.2013

Additional Information

Plain Text

>> Diabetes mellitus type 2 is one of the most common chronic diseases in Germany. According to the current study on the health of adults in Germany (DEGS) by the Robert Koch Institute (RKI), the lifetime prevalence of known diabetes in the population between 18 and 79 years of age is expected to be 7.2 percent or 4.6 million people . According to the RKI, this estimate is lower than previous prevalence estimates from healthcare data (see RKI 2012). However, the estimates of the prevalence of diabetes and its growth rates in Germany vary significantly.
There is significantly less uncertainty regarding the figures for outpatient statutory health insurance prescriptions, as these are continuously recorded by INSIGHT Health, among others, as part of an almost complete survey (National Prescription Information, NVI).
The GKV market for oral antidiabetic drugs (OAD) will be examined below. It's hand...

...

Do you want to leave us already?

Subscribe to our newsletter quickly. Then you can be sure that you won't miss anything.